E2020 inhibitor of acetyl cholinesterase: Phase III trial in 1000 patients has ended with results, which the company described as encouraging, to be published l

Eisai Co. Ltd., Toyko Product: E2020 inhibitor of acetyl cholinesterase Indication: Mild to moderate dementia associated with Alzheimer's disease Status: Phase III trial in 1000 patients has ended w...